Abstract
Background The long-term effects of Legionnaires’ disease beyond the acute infection and their impact on healthcare utilisation remain poorly understood. We present the rationale and study design of a matched prospective observational cohort study (LongLEGIO) aimed at investigating the persistent sequelae on patients’ health, well-being, and health service use following community-acquired Legionnaires’ disease, compared to other bacterial pneumonias that tested negative for Legionella.
Methods Patients with Legionnaires’ disease and other bacterial Legionella test-negative pneumonia are recruited from secondary and tertiary care hospitals and matched for sex, age, hospital-level and date of diagnosis. Semi-structured interviews were conducted at baseline (shortly after the pneumonia diagnosis) and at two, six and 12 months following appropriate antibiotic therapy. Baseline assessments capture pre-existing conditions, illness experience, and disease severity, while follow-up assessments evaluate long-term symptoms, healthcare utilisation, quality of life (EQ-5D-5L), and social/work impacts. Data on case management and the disease severity are extracted from patient records.
Results A total of 59 patients with community-acquired Legionnaires’ disease and 60 patients with other bacterial Legionella test-negative pneumonia were enrolled. Both cohorts were representative of their respective condition. Key differences between Legionnaires’ disease and non-Legionella bacterial pneumonia patient groups emerged in terms of comorbidities, pneumonia severity, and self-reported quality of life. These differences will be accounted for in future analyses as part of the LongLEGIO study.
Conclusions The LongLEGIO study will advance ongoing research on post-acute infection syndromes and provide a robust data foundation for more accurate assessments of the disease burden associated with Legionnaires’ disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This LongLEGIO study received no extra funding. The parent SwissLEGIO project is funded by the Swiss Federal Office of Public Health (grant nr: 142004673).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Commission of Northwestern and Central Switzerland gave ethical approval for this work (nr.: 2023-00639).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
